Lanosterol eye drops have not been proven to treat cataracts in humans. The idea traces back to a widely publicized 2015 study in which lanosterol dissolved protein clumps in rabbit and dog lenses, but no completed human clinical trial has confirmed that result. Animal data remain genuinely interesting, and research is still active, but the gap between dissolving aggregates in a lab dish and clearing a person’s cloudy lens with a topical drop is enormous and largely unbridged.
How Cataracts Form and Why Dissolving Them Is Hard
The human lens is packed with proteins called crystallins, which are arranged in a precise, transparent structure. Over a lifetime, cumulative damage from ultraviolet light, oxidation, and other chemical changes causes those proteins to misfold and clump together into insoluble aggregates that scatter light.1PubMed Central. Protein misfolding and aggregation in cataract disease and prospects for prevention That scattering is what you see as the milky cloudiness of a cataract. The aggregation can follow different pathways and produce varied clump structures depending on which crystallin subtypes are involved and what triggered the damage.2PubMed Central. Function and Aggregation in Structural Eye Lens Crystallins
A key player is alpha-crystallin, which normally acts as a built-in chaperone, catching other proteins before they aggregate. But alpha-crystallin itself can be overwhelmed or damaged. Research has shown that both αA- and αB-crystallin form aggregates under aging-related cataract conditions, while oxidation- or diabetes-driven cataracts primarily involve αB-crystallin aggregation.3Scientific Reports. Phase separation of α-crystallin-GFP protein and its implication in cataract disease This matters because any drug that claims to reverse cataracts needs to undo aggregation in multiple protein types across multiple damage pathways. It is not one problem but a family of related problems, which is part of why a single molecule has struggled to deliver consistent results.
The 2015 Study That Made Headlines
In July 2015, a team led by Ling Zhao published a paper in Nature that generated worldwide excitement. The researchers had noticed that children in two families with severe congenital cataracts carried mutations in the gene for lanosterol synthase, an enzyme in the cholesterol-making pathway.4PubMed. Lanosterol reverses protein aggregation in cataracts That genetic clue had precedent: earlier work in rats had already linked lanosterol synthase mutations to cataract formation.5PubMed Central. Lanosterol synthase mutations cause cholesterol deficiency-associated cataracts in the Shumiya cataract rat
Zhao’s group then ran a series of experiments. Lanosterol treatment shrank preformed protein aggregates in cell cultures. It reduced cloudiness in dissected rabbit lenses soaking in a lab solution. And when given to dogs with naturally occurring cataracts, it appeared to lower cataract severity in living eyes.4PubMed. Lanosterol reverses protein aggregation in cataracts The paper concluded that lanosterol pointed toward “a novel strategy for cataract prevention and treatment.”
Media coverage was euphoric. Headlines suggested eye drops could soon replace surgery. Pet owners began asking veterinarians about the treatment. The study remains one of the most-discussed cataract papers of the past decade. But the scientific follow-up has been far messier than those headlines implied.
When Other Labs Tried to Replicate the Results
One of the most pointed challenges came from a 2019 study published in Scientific Reports. Researchers tested whether lanosterol and related oxysterols could bind to αB-crystallin, the chaperone protein central to many cataracts. Using both laboratory binding assays and computational modeling, they found that lanosterol failed to reach acceptable binding scores for αB-crystallin compared to a control molecule. Their conclusion was blunt: oxysterols like lanosterol did not appear to interact with αB-crystallin in a way that would reverse aggregation.6PubMed Central. Failure of Oxysterols Such as Lanosterol to Restore Lens Clarity from Cataracts
That does not necessarily invalidate the original finding, though. Cataracts involve multiple crystallin types, and other work has found that lanosterol does bind to gamma-D-crystallin, a different lens protein. Computational simulations showed that lanosterol preferentially attaches to hydrophobic regions on gamma-D-crystallin’s surface, specifically near the structured end of the molecule, and does so with stronger affinity than lanosterol molecules have for each other.7JACS. Lanosterol Disrupts the Aggregation of Amyloid-β Peptides A 2025 study added another layer, finding that at 75 micromolar concentration, lanosterol significantly suppressed αB-crystallin aggregation under UV-A exposure through a chemical reaction that prevents harmful disulfide bonds from forming.8PubMed. Molecular mechanism of lanosterol binding to αB-crystallin for inhibition of UV-A induced aggregation
So the picture is not simply “it works” or “it doesn’t.” Lanosterol appears to interact meaningfully with some crystallin proteins under some conditions but not others. Whether that selective activity is enough to clear a real, mature human cataract remains unresolved. The most honest reading of the literature is that lanosterol has genuine anti-aggregation activity in certain experimental setups, but the original dog study’s dramatic results have proven difficult to reproduce consistently across different cataract models and crystallin targets.
The Drug Delivery Problem
Even if lanosterol worked perfectly against every type of crystallin aggregate, getting it into the lens would still be a major obstacle. The eye has multiple barriers between a drop on the surface and the lens sitting behind the iris. Tears wash away most of a topical drop within seconds. The corneal epithelium blocks large and hydrophobic molecules. And the lens itself has no blood supply, so systemic delivery is not an option either. These anatomical and physiological barriers are a well-recognized bottleneck for any anti-cataract drug, not just lanosterol.9PubMed Central. Breaking Barriers: Nanomedicine-Based Drug Delivery for Cataract Treatment
Lanosterol is especially tricky because it is a sterol, meaning it is a waxy, fat-soluble molecule that does not dissolve easily in the watery fluid of the eye. Standard eye drop formulations struggle to keep it in solution at therapeutic concentrations. This is likely part of why the original 2015 study worked in dissected lenses soaking directly in a lanosterol bath and in dog eyes receiving intravitreal injections or high-dose topical applications but has been hard to translate into a simple over-the-counter drop.
Researchers are exploring nanoparticle formulations that could improve penetration into the front of the eye and sustain drug release over time. One team in monkeys tested a subconjunctival thermogel implant, essentially a slow-release depot placed just under the thin membrane covering the white of the eye. The implant delivered lanosterol over weeks without causing tissue scarring or significant inflammation, and slit-lamp exams showed no corneal damage.10Precision Clinical Medicine. Inhibitory effect of lanosterol on cataractous lens of cynomolgus monkeys using a subconjunctival drug release system That kind of implant is a far cry from a simple eye drop, but it may be more realistic for delivering enough lanosterol to affect the lens.
What the Monkey Studies Actually Showed
The cynomolgus monkey study deserves attention because primates are a much closer model to human eyes than rats or dogs. In monkeys with cortical cataracts treated via the subconjunctival lanosterol system, the proportion of soluble protein in the lens cortex was higher than in untreated controls, roughly 78% compared to 67%. The ratio of soluble alpha-crystallin to total protein was also higher in the treated group. Lanosterol exposure increased the total antioxidant capacity in both the cortex and the nucleus of the lens.10Precision Clinical Medicine. Inhibitory effect of lanosterol on cataractous lens of cynomolgus monkeys using a subconjunctival drug release system
There are caveats. The effect was clearest in cortical cataracts, not nuclear cataracts, the most common age-related type in many populations. The solubility improvement for beta- and gamma-crystallins was not significant in either cortical or nuclear cataract groups. So even in the best primate data available, lanosterol helped with one subtype of protein aggregation in one region of the lens. That is meaningful, but it is not “lanosterol reverses cataracts” in the sweeping sense the early headlines implied.
A Different Approach: mRNA Instead of the Molecule Itself
One of the more creative strategies comes from a 2025 paper that skipped lanosterol entirely and instead delivered the genetic instructions for lanosterol synthase directly into the eye. The idea is to let the eye’s own cells produce lanosterol locally. Researchers packaged human lanosterol synthase mRNA inside lipid nanoparticles and injected them into the eyes of rats with cataracts. The treatment produced no significant eye lesions, no organ damage, and no changes in blood chemistry compared to untreated animals.11Nature Communications. Ocular delivery of lipid nanoparticles-formulated mRNA encoding lanosterol synthase ameliorates cataract in rats
This approach sidesteps the drug delivery problem by turning the eye into its own lanosterol factory. It is a clever proof of concept, but mRNA therapeutics for the eye are at a very early stage, and injecting nanoparticles into a rat eye is orders of magnitude simpler than developing a product millions of people could use safely.
Other Molecules in the Pipeline
Lanosterol is not the only small molecule being studied for cataracts. A team at the University of California identified a compound called VP1-001, an oxysterol that partially restored lens clarity in mice with both genetic and age-related cataracts. Critically, when they tested the mirror-image version of the molecule (its enantiomer), it had no effect, which suggests VP1-001 works through a specific binding interaction with alpha-B-crystallin rather than through a nonspecific chemical process.12PubMed Central. Mechanism of Action of VP1-001 in cryAB(R120G)-Associated and Age-Related Cataracts
A separate group screened thousands of FDA-approved drugs and natural compounds and found that closantel, an existing antiparasitic drug, and gambogic acid, a plant-derived compound, could suppress heat-driven crystallin aggregation in lab assays. Both appeared to work by binding to hydrophobic pockets on crystallin surfaces.13PubMed Central. α-Crystallin chaperone mimetic drugs inhibit lens γ-crystallin aggregation: Potential role for cataract prevention Another approach used a thermal stability screen to find molecules that bind to both αA- and αB-crystallin and reversed aggregation. The most promising compound improved transparency in mouse models of hereditary cataract and partially restored protein solubility in aged mouse lenses and in human lenses tested outside the body.14PubMed Central. Pharmacological chaperone for α-crystallin partially restores transparency in cataract models
None of these have reached human trials either, but their existence is important context. Lanosterol opened a door, and the field has fanned out to explore a whole class of potential anti-cataract molecules. The eventual treatment, if one emerges, might not be lanosterol itself but something inspired by it.
What About the Drops Sold Online
If you search for lanosterol eye drops, you will find products for sale. Some are marketed for pets, some for humans, and they range from under twenty dollars to well over a hundred. These products exist in a regulatory gray zone. Because lanosterol is not an approved drug for cataracts in any country, these drops are typically sold as “supplements” or “research compounds” without any claim of clinical efficacy on the label, even if the marketing materials strongly imply they work.
There are several problems with using them. First, the concentration and formulation vary wildly between products, and there is no standard manufacturing process for ophthalmic lanosterol. Second, as discussed, lanosterol’s poor water solubility means that a simple aqueous eye drop may not deliver meaningful amounts to the lens. Third, none of these products have been tested in controlled human trials for safety or effectiveness. The monkey thermogel study showed safety for a sustained-release depot system, but that is a very different delivery method from a drop dripped onto the surface of the eye. Fourth, cataracts progress slowly in most people, which makes it easy to attribute normal fluctuations in vision to whatever supplement you started taking.
Veterinarians occasionally report anecdotes of pet owners trying lanosterol drops for dogs with cataracts, inspired by the 2015 study. Results are inconsistent at best, and no veterinary regulatory body has approved lanosterol for animal cataracts either.
Why Surgery Still Dominates
Cataract surgery is one of the most commonly performed and successful operations in medicine. The cloudy natural lens is broken up with ultrasound and replaced with an artificial intraocular lens. Recovery is rapid, complication rates are low, and outcomes are predictable. It is so effective that the bar for a drug to compete is extraordinarily high: you need to either prevent cataracts entirely in the decades before they form, or reverse them enough to avoid surgery in a large share of patients.
A drug that slows progression by a few years would still have enormous public health value, particularly in parts of the world where surgery is inaccessible. But even that more modest goal has proven elusive. A large trial in South India tested antioxidant supplements, including beta-carotene and vitamins C and E, in a population with high cataract rates and generally poor antioxidant intake. The supplements showed no significant effect on cataract progression compared to placebo.15PubMed Central. The Antioxidants in Prevention of Cataracts Study: effects of antioxidant supplements on cataract progression in South India If high-dose antioxidants couldn’t move the needle in a population seemingly primed to benefit, the challenge facing any anti-cataract drug is clear.
Different Cataract Types Respond Differently
One underappreciated wrinkle is that cataracts are not all the same. Nuclear cataracts form in the center of the lens and are the classic age-related type; cortical cataracts start at the lens periphery; and posterior subcapsular cataracts develop on the back surface. Each type affects vision differently. Nuclear cataracts often cause a progressive myopic shift, while cortical cataracts tend to produce astigmatism changes, and posterior subcapsular cataracts can create severe glare.16PubMed Central. Refractive changes in nuclear, cortical and posterior subcapsular cataracts. effect of the type and grade
This matters for lanosterol because the available evidence, particularly the monkey data, suggests lanosterol’s effects differ by cataract type. The improvement in protein solubility and antioxidant capacity was concentrated in cortical cataracts. Nuclear cataracts, where protein crosslinking tends to be more advanced and the lens core is denser, showed less response. A future drug might need to be targeted to specific cataract subtypes rather than marketed as a universal solution. That kind of precision would require diagnostic tools to identify the cataract type early, which adds another layer of complexity to any real-world treatment pathway.
How Far Away Is a Real Treatment
As of mid-2025, no lanosterol-based treatment has completed a human clinical trial for cataracts. The field is still solving fundamental problems: which molecule works best, how to get it into the lens at sufficient concentration, which cataract types it might help, and whether the effect is large enough to matter clinically. The mRNA approach is exciting but adds its own regulatory and manufacturing hurdles. The alternative small molecules like VP1-001 are still in early-stage animal work.
The honest assessment is that lanosterol eye drops, as a product you could buy and use to treat cataracts, do not work in any clinically validated sense. The underlying science is real and progressing, and it is not unreasonable to think that some form of pharmacological cataract treatment could emerge in the next decade or two. But the version of that story where you put drops in your eyes and your cataracts melt away is still firmly in the future, if it arrives at all. Anyone with visually significant cataracts today should be discussing surgical options with an ophthalmologist, not experimenting with unregulated drops based on a decade-old animal study.